四碘甲状腺乙酸
| 中文名称 | 四碘甲状腺乙酸 |
|---|---|
| 中文同义词 | 左旋甲状腺素EP杂质D;3,3',5,5'-四碘甲腺-乙酸;四碘甲状腺乙酸;4-(4-羟基-3,5-二碘苯氧基)-3,5-二碘苯乙酸;左甲状腺素–杂质D;左甲状腺素EP杂质D;碘塞罗宁杂质D (EP);碘塞罗宁 EP杂质D |
| 英文名称 | 3,3',5,5'-TETRAIODOTHYRO-ACETIC ACID |
| 英文同义词 | 3,3’,5,5’-tetraiodo-thyroaceticaci;3,5-diiodo-4-(4-hydroxy-3,5-diiodophenoxy)-benzeneaceticaci;3,5-diiodo-4-(4-hydroxy-3,5-diiodophenoxy)benzeneaceticacid;acide3,5,3’,5’-tetraiodothyroacetique;tetraiodothyroaceticacid;4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenylacetic acid;3,5-DIIODO-4-(4-HYDROXY-3,5-DIIODOPHENOXY)PHENYLACETIC ACID;4-[4-HYDROXY-3,5-DIIODOPHENOXY]-3,5-DIIODOBENZENEACETIC ACID |
| CAS号 | 67-30-1 |
| 分子式 | C14H8I4O4 |
| 分子量 | 747.83 |
| EINECS号 | 200-649-1 |
| 相关类别 | 合成;有机中间体;杂质对照品;Aromatic Phenylacetic Acids and Derivatives;Aromatics;Drug Analogues;Impurities;Intermediates & Fine Chemicals;Pharmaceuticals |
| Mol文件 | 67-30-1.mol |
| 结构式 |  |
四碘甲状腺乙酸 性质
| 熔点 | 219-220 °C (decomp) |
|---|---|
| 沸点 | 544.8±50.0 °C(Predicted) |
| 密度 | 2.727±0.06 g/cm3(Predicted) |
| 储存条件 | Keep in dark place,Sealed in dry,Store in freezer, under -20°C |
| 溶解度 | 丙酮：可溶 19.60 - 20.40mg/mL，透明，无色（或淡黄色至黄色） |
| 形态 | 粉末晶体 |
| 酸度系数(pKa) | 3.98±0.10(Predicted) |
| 颜色 | 白色到黄色到绿色 |
| InChIKey | PPJYSSNKSXAVDB-UHFFFAOYSA-N |
Tetrac (Tetraiodothyroacetic acid)，L-甲状腺素 (T4) 的天然衍生物，是甲状腺素整合素受体拮抗剂。Tetrac 阻断 T4 和 3,5,3'-triiodo-L-thyronine (T3) 在整联蛋白 αvβ3 上甲状腺激素的细胞表面受体处的作用。Tetra 具有抗血管生成和抗肿瘤活性。
Tetrac (0.01-1 μM; 2-6 d) induces anti-proliferation in HT-29 and HCT116 cells with different
K-RAS
status.
Tetrac (0.1 μM; 30 min) inhibits activation of ERK1/2 in HT-29 and HCT116 cells.
Tetrac (0.1 μM; 24 h) inhibits expression of
CCND1
and
c-Myc
, but promotes expression of
CASP2
and
THBS1
.
Cell Proliferation Assay
| Cell Line: | HT-29 and HCT116 cells |
| Concentration: | 0.01, 0.1, 1 μM |
| Incubation Time: | 0, 2, 4, 6 days |
| Result: | Induced anti-proliferation of K-RAS wild-type colorectal cancer cells. |
Western Blot Analysis
| Cell Line: | HT-29 and HCT116 cells |
| Concentration: | 0.1 μM |
| Incubation Time: | 30 min |
| Result: | Inhibited constitutively activated ERK1/2, and this inhibition can remove by anti-integrin αvβ3 antibody pretreatment. |
Tetrac (35 μg; p.o. for 40 days) inhibits tumor inoculation, growth and integrin expression in mice.
| Animal Model: | Wild-type male Balb/C mice aged 8 weeks are inoculated with 102B16F10 or B16LS9 cells |
| Dosage: | 35 μg per day |
| Administration: | P.o. (added to the drinking water) daily for 40 days |
| Result: |
Delayed the onset of ocular melanoma.
Reduced the S-100 and integrin staining level in the B16F10 mice model. |
| 提供商 | 语言 |
|---|---|
|
英文
|